BiVACOR has developed a Total Artificial Heart (TAH) that offers a new lifeline for patients with end-stage heart failure, aiming to bridge the gap to transplantation and potentially serve as a long-term solution.
Photo source:
Bivacor
The BiVACOR TAH distinguishes itself through several key features:
Single Moving Part: The device incorporates a magnetically levitated rotor that serves as the sole moving component, reducing mechanical wear and enhancing durability.
Dual Circulation Support: This rotor simultaneously pumps blood to both systemic and pulmonary circulations, effectively replacing the function of both ventricles.
Compact and Durable: Constructed from titanium, the TAH is designed to fit within the chest cavity of most adults, offering a robust and biocompatible solution.
BiVACOR's TAH has achieved significant clinical milestones:
First-in-Human Implantation: In July 2024, surgeons at Baylor St. Luke’s Medical Center in Houston successfully implanted the BiVACOR TAH into a patient with end-stage heart failure, marking a pivotal moment in artificial heart technology.
Subsequent Implants: Following the initial success, additional implantations have been performed, including a notable case at Duke University Hospital where the TAH effectively supported a patient until a donor heart became available.
As clinical trials progress, the BiVACOR TAH holds the potential to transform the landscape of heart failure treatment, providing a viable option for patients who may not have access to timely heart transplants. Ongoing research and development aim to refine the device further, enhancing its functionality and patient compatibility.
Please subscribe to have unlimited access to our innovations.